The following information is intended as a resource for journalists only and was factually correct at the time it was issued.

Follow AbbVie UK

Tags

“We all have a part to play in making sure the NHS can meet the challenges it faces” says Alan Milburn

“We all have a part to play in making sure the NHS can meet the challenges it faces” says Alan Milburn

Press releases   •   May 04, 2017 00:01 BST

AbbVie’s new Live:Lab programme launches today and aims to improve the nation’s health through addressing the ‘Fear of Finding Out’ - focusing on prevention

Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR12 Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C

Press releases   •   Apr 21, 2017 00:01 BST

95 percent of patients infected with genotype 3 (GT3) chronic hepatitis C virus (HCV), without cirrhosis and who are new to treatment, achieved SVR12 with 8 weeks of treatment

AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR12 Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis

Press releases   •   Apr 20, 2017 00:01 BST

New data demonstrated high SVR12 rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment

NHS England to routinely commission AbbVie’s HUMIRA® (adalimumab) for adults with severe refractory uveitis

Press releases   •   Mar 13, 2017 00:01 GMT

NHS England publishes Interim Clinical Commissioning Policy recommending AbbVie’s HUMIRA® (adalimumab) for adults with severe refractory uveitis

AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C

Press releases   •   Feb 27, 2017 00:01 GMT

CHMP opinion grants AbbVie approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to moderate fibrosis

‘Fear of Finding Out’ Makes up a Third of Conscious Reasons Why We Don’t Visit The Doctor

‘Fear of Finding Out’ Makes up a Third of Conscious Reasons Why We Don’t Visit The Doctor

Press releases   •   Jan 30, 2017 16:00 GMT

Unhealthy people are less likely to visit the GP due to the ‘Fear of Finding Out'

European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorisation Application for AbbVie’s Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

Press releases   •   Jan 24, 2017 00:01 GMT

If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis